View Supplemental Materials

Beacons of Hope: Discussing Naloxone with Patients

Activity Details
  • Credit Amounts:
    • CME: 0.50
    • CPE: 0.50
    • Other: 0.50
    • ASWB ACE: 0.50
    • CNE: 0.50
  • Cost: Free
  • Release: Jan 17, 2024
  • Expires: Jan 17, 2027
  • Estimated Time to Complete:
    30 Minutes
  • Average User Rating:
    (5 Ratings)

Faculty

Melanie Dicks Melanie Dicks, PharmD
Clinical Assistant Professor, Pharmacy Practice and Science
University of Kentucky College of Pharmacy
Lexington, Kentucky


Needs Statement

Current primary care practice sites are ripe with patients who may need naloxone as a reversal agent to be used in the event of an opioid overdose or emergency. Primary care providers need additional education and information on how to adequately speak with their patients about the use of naloxone for opioid overdose or emergencies.

Target Audience

Healthcare professionals in a primary care setting.

Objectives

Upon completion of this educational activity, learners will be able to:
1. Describe what Narcan® (naloxone) is in basic terms to your patients.
2. Explain Narcan’s® (naloxone’s) basic use and place in therapy for patients.
3. Discuss with patients the three broad steps of opioid overdose response with Narcan® (naloxone).
4. Discuss how to obtain Narcan® (naloxone) and some general regulations for access with patients.

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0421-H.75-UK5C

IPE Competencies

  • Roles/ Responsibilities
  • Interprofessional Communication

CPE
This knowledge-based activity will award 0.50 contact hours (0.050 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Other
UK Healthcare CECentral certifies this activity for 0.50 hours of participation.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 0.50 clinical continuing education credits.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 nursing contact hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months.  An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgement

The activity was supported by Anthem.